Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hypercholesterolemia

Hypercholesterolemia

Part of Hyperlipidemia

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hypercholesterolemia

191 trials tracked for Hypercholesterolemia: 110 in phase 3 or 4 and 28 with published results. The most-cited published study has 1149 citations.

191Trials tracked
110Phase 3 & 4
0Recruiting
28With published results
Phase distribution
Phase 4 28 Phase 3 82 Phase 2 41 Phase 1 7 Other / NA 33
  1. Phase 3 GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound Completed · 1,149 cited
  2. Phase 3 Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony) Completed · 792 cited
  3. Phase 4 Effect On Serum Cholesterol Of Dairy Products With Addition Of Esterified Phytosterols Completed · 743 cited
  4. Phase 3 Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk Completed · 477 cited
  5. Phase 3 Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant Completed · 430 cited
  6. Phase 3 Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility) Completed · 421 cited
Show 44 more trials
  1. Phase 3 Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan Completed · 126 cited
  2. Phase 3 Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1) Completed · 124 cited
  3. Phase 3 Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II) Completed · 102 cited
  4. Phase 4 Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia Completed · 86 cited
  5. Phase 3 Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies Completed · 79 cited
  6. Phase 3 Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia Completed · 71 cited
  7. Phase 3 Open Label Study of Long Term Safety Evaluation of Alirocumab Completed · 58 cited
  8. Phase 3 Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia Completed · 49 cited
  9. Phase 3 Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies Completed · 48 cited
  10. Phase 3 Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. Completed · 43 cited
  11. Phase 3 An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia Completed · 39 cited
  12. Phase 3 A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH) Completed · 33 cited
  13. Phase 4 Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression Completed · 32 cited
  14. Phase 3 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4 Completed · 29 cited
  15. Phase 3 Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin Completed · 22 cited
  16. Phase 3 A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol Completed · 20 cited
  17. Phase 3 Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439) Completed · 13 cited
  18. Phase 3 Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy. Completed · 13 cited
  19. Phase 3 Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia Completed · 7 cited
  20. Phase 3 A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) Completed · 5 cited
  21. Phase 3 Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE) Completed · 2 cited
  22. Phase 4 Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia Completed · 1 cited
  23. Phase 4 Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia Completed
  24. Phase 4 A Study Comparing CoQ10 Levels While Taking 3 Different Statins Completed
  25. Phase 4 Alirocumab in Patients With Acute Myocardial Infarction Completed
  26. Phase 4 Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2) Completed
  27. Phase 4 Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo Completed
  28. Phase 4 Effect of Atorvastatin on Bone-vascular Axis Completed
  29. Phase 4 Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet Completed
  30. Phase 4 Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED) Completed
  31. Phase 4 Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL) Completed
  32. Phase 4 Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet Completed
  33. Phase 4 Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol Completed
  34. Phase 4 Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol Completed
  35. Phase 4 Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED) Completed
  36. Phase 4 Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355) Completed
  37. Phase 4 Effects of Ezetimibe on the Absorption of Oxidized Cholesterol Completed
  38. Phase 4 Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors Completed
  39. Phase 4 A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction Completed
  40. Phase 4 Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study Completed
  41. Phase 4 The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED) Completed
  42. Phase 4 Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED) Completed
  43. Phase 4 Bioavailability Study for New Atorvastatin Formulation Completed
  44. Phase 4 A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541) Completed

Showing the 50 most-cited and recently-updated of 191 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Lipid lowering therapy patterns in patients with ASCVD and familial hypercholesterolemia in Israel
Cardiology Cohort
Lipid lowering therapy patterns in patients with ASCVD and familial hypercholesterolemia in Israel Lipid lowering therapy patterns observed in Israeli patients
This retrospective database study examined lipid lowering therapy patterns among patients with atherosclerotic cardiovascular disease, ASCVD…
A look at how patients with high cholesterol and heart disease manage their lipid lowering therapy and treatment adherence in Israel.
Frontiers Apr 30, 2026
Bempedoic acid 180 mg/day reduces LDL-C in Japanese patients with hypercholesterolemia over 52 weeks
Drug Pipeline Phase III
Bempedoic acid 180 mg/day reduces LDL-C in Japanese patients with hypercholesterolemia over 52 weeks New Cholesterol Option Works Well for Statin Intolerant Patients
This multicenter, open-label, single-arm Phase 3 study evaluated bempedoic acid 180 mg/day in 130 Japanese patients with hypercholesterolemi…
A new cholesterol drug safely lowers bad cholesterol for one year in patients who cannot take standard statin medications.
Apr 17, 2026
Night shift work linked to elevated total cholesterol in male miners, cross-sectional analysis finds
Psychiatry Cohort
Night shift work linked to elevated total cholesterol in male miners, cross-sectional analysis finds Your Shift Work Raises Cholesterol Even If You Sleep Well
A cross-sectional analysis of 921 male underground miners in the Kailuan Group found night shift work (0:00–7:59) was associated with higher…
Night shift work raises cholesterol levels even when workers sleep well, proving that fixing your sleep isn't enough to protect your heart h…
Frontiers Apr 14, 2026
NHANES data show prevalence of high total cholesterol among US adults aged 20+
Infectious Disease
NHANES data show prevalence of high total cholesterol among US adults aged 20+ How many American adults have high cholesterol? A new look at national data
An observational analysis of NHANES 2015-2018 data examined the prevalence of high total cholesterol among US adults aged ≥20 years.
A new look at national data reveals how many American adults aged 20 and older have high total cholesterol, a silent driver of heart disease…
CDC Apr 6, 2026
Meta-analysis finds water-only fasting decreases HDL, increases LDL and total cholesterol
Diabetes & Endocrinology Meta-analysis
Meta-analysis finds water-only fasting decreases HDL, increases LDL and total cholesterol Does water-only fasting help your cholesterol? A new review suggests it might not
A systematic review and meta-analysis of 32 human studies examined water-only fasting effects on blood lipids.
Water-only fasting may lower good cholesterol and raise bad cholesterol, according to a new review of 32 human studies.
Frontiers Apr 4, 2026
Phase 3 trial of oral PCSK9 inhibitor enlicitide in hypercholesterolemia reports no results
Diabetes & Endocrinology Phase III
Phase 3 trial of oral PCSK9 inhibitor enlicitide in hypercholesterolemia reports no results Can a new pill lower cholesterol as well as existing drugs?
A completed phase 3 randomized controlled trial in 301 adults with hypercholesterolemia compared oral PCSK9 inhibitor enlicitide to ezetimib…
A new cholesterol pill called enlicitide finished its final trial, but the results showing how well it lowers bad cholesterol and its safety…
CT.gov Apr 3, 2026

Research across Hyperlipidemia

Related studies from across the Hyperlipidemia family.

Narrative review on PCSK9 inhibitors for familial hypercholesterolemia
Drug Pipeline Sys. Review
Narrative review on PCSK9 inhibitors for familial hypercholesterolemia Review explores PCSK9 inhibitors for familial hypercholesterolemia
This narrative review synthesizes evidence on PCSK9 inhibitors, including evolocumab, for familial hypercholesterolemia. The authors discuss…
This review looks at PCSK9 inhibitors like evolocumab for people with familial hypercholesterolemia. It discusses how these drugs work and t…
Frontiers May 27, 2026

Questions about Hypercholesterolemia

Did the phase 3 trial of oral PCSK9 inhibitor enlicitide show results?

Yes, phase 3 trials of oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions of about 60% compared to placebo and superiority over ezetimibe and bempedoic acid.

Full answer →
How do lipid lowering therapy patterns differ in patients with familial hypercholesterolemia?

Patients with familial hypercholesterolemia often require combination therapy (statins plus ezetimibe or PCSK9 inhibitors) but many still fail to reach LDL-C targets, highlighting gaps in treatment intensification.

Full answer →
How does night shift work affect total cholesterol levels in male miners?

Night shift work is linked to higher total cholesterol in male miners, independent of sleep quality, based on cross-sectional and prospective studies.

Full answer →